Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Formula E is set to get a lot faster with the introduction of the GEN3 Evo, the quickest accelerating FIA single-seater race car – Capable of 0-60mph in 1.82 seconds (0-100kph in 1.86s). Set to race ...

As we approach the start of Formula 1’s launch season, plenty of new faces in new team colors are going to be on show. Lewis Hamilton and (…) ...